Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)

Basit Öğe Kaydı
dc.authorid0000-0002-2035-9462
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorTekgündüz, Emre
dc.contributor.authorKozanoğlu, İlknur
dc.contributor.authorÖzkan, Hasan Atilla
dc.contributor.authorAksu, Salih
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorDemirkan, Fatih
dc.date.accessioned2022-04-28T11:47:29Z
dc.date.available2022-04-28T11:47:29Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractGraft versus host disease (GVHD) is still the most important cause of mortality and morbidity after allogeneic stem cell transplantation. Though perfect response rates are not achieved, steroids are still the first-line treat-ment. In the face of the presence of the drugs approved by FDA in recent years for acute and chronic GVHD as second-line therapy in the steroid-refractory group, there exists no standard approach. Extracorporeal photopheresis (ECP) with an immunomodulatory effect, is favored in the treatment of both acute and chronic steroid refractory GVHD as it does not increase the risk of relapses or infections. Having a low profile of side effects, ECP is also generally well-tolerated by patients. Being a time requiring procedure, the fact is that it is not able to be practiced in all health centers and requires central venous catheters in patients unfit for venous access may be enumerated among its shortcomings. No complete standard is available with respect to ECP application frequency-time; it varies from one center to another. The Turkish Society of Apheresis established the Turkish ECP (TECP) group and sought some answers to the questions regarding the use of ECP in the treatment of GVHD, and issued a position statement.
dc.identifier.citationKaynar, L., Tekgündüz, E., Kozanoğlu, İ., Özkan, H. A., Aksu, S., Özkalemkaş, F. ... Demirkan, F. (2022). Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA). Transfusion and Apheresis Science, 61(1). https://doi.org/10.1016/j.transci.2022.103373
dc.identifier.doi10.1016/j.transci.2022.103373
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1
dc.identifier.pmid35123893
dc.identifier.scopus2-s2.0-85124214906
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2022.103373
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9386
dc.identifier.volume61
dc.identifier.wos000766631700008en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaynar, Leylagül
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute Graft Versus Host Disease
dc.subjectChronic Graft Versus Host Disease
dc.subjectExtracorporeal Photopheresis
dc.titleExtracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kaynar-Leylagul-2022.pdf
Boyut:
476.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu